# Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

> **NCT03037606** · PHASE4 · COMPLETED · sponsor: **Neutec Ar-Ge San ve Tic A.Ş** · enrollment: 48 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Rabelis DDR 50 mg Capsules
- **DRUG:** Pariet 20 mg Enteric Coated Tablets

## Key facts

- **NCT ID:** NCT03037606
- **Lead sponsor:** Neutec Ar-Ge San ve Tic A.Ş
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03037606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03037606, "Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03037606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*